Flow cytometric assessment of amphotericin B susceptibility in Leishmania infantum isolates from patients with visceral leishmaniasis

被引:45
作者
Di Giorgio, C
Faraut-Gambarelli, F
Imbert, A
Minodier, P
Gasquet, M
Dumon, H
机构
[1] Fac Pharm Marseille, Lab Parasitol Hyg & Zool, F-13385 Marseille 05, France
[2] Fac Med, Parasitol Lab, Marseille, France
[3] Hop Nord, Serv Pediat Pr Garnier, Marseille, France
关键词
D O I
10.1093/jac/44.1.71
中图分类号
R51 [传染病];
学科分类号
100401 [流行病与卫生统计学];
摘要
Amphotericin B susceptibility was measured by a flow cytometric membrane potential assay in Leishmania infantum promastigotes isolated from 11 immunocompetent children treated with liposomal amphotericin B and 19 HIV-infected young adults treated with intralipid amphotericin B. Susceptibility levels were measured by the 90% inhibitory concentrations (IC90) representing the concentrations of drug that induced a 90% decrease in membrane potential compared with the control culture. In immunocompetent children, treatment was fully effective whatever the susceptibility of isolates to amphotericin B. In immunocompromised adults, on the contrary, unresponsiveness and relapses could be observed in all cases and IC90 increased in the course of successive treatments: a decrease of amphotericin B susceptibility in both promastigote and amastigote forms could be observed in a patient who had six relapses. These results suggest that the success of amphotericin B treatment depends greatly on patient immunity status, and indicate that successive relapses could enhance emergence of amphotericin B resistant isolates. The results demonstrate that the flow cytometric membrane potential assay can be used as an easy and reliable tool for studying the evolution of interactions between amphotericin B and the parasite membrane during long-term treatments.
引用
收藏
页码:71 / 76
页数:6
相关论文
共 29 条
[1]
Azas N, 1997, CYTOMETRY, V28, P165, DOI 10.1002/(SICI)1097-0320(19970601)28:2&lt
[2]
165::AID-CYTO10&gt
[3]
3.0.CO
[4]
2-O
[6]
Human leishmaniasis: Clinical, diagnostic, and chemotherapeutic developments in the last 10 years [J].
Berman, JD .
CLINICAL INFECTIOUS DISEASES, 1997, 24 (04) :684-703
[7]
AMPHOTERICIN-B - CURRENT UNDERSTANDING OF MECHANISMS OF ACTION [J].
BRAJTBURG, J ;
POWDERLY, WG ;
KOBAYASHI, GS ;
MEDOFF, G .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (02) :183-188
[8]
An axenic amastigote system for drug screening [J].
Callahan, HL ;
Portal, AC ;
Devereaux, R ;
Grogl, M .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (04) :818-822
[9]
Epidemiologic surveillance of visceral leishmaniasis in Sicily, Italy [J].
Cascio, A ;
Gradoni, L ;
Scarlata, F ;
Gramiccia, M ;
Giordano, S ;
Russo, R ;
Scalone, A ;
Camma, C ;
Titone, L .
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 1997, 57 (01) :75-78
[10]
Liposomal amphotericin B - Therapeutic use in the management of fungal infections and visceral leishmaniasis [J].
Coukell, AJ ;
Brogden, RN .
DRUGS, 1998, 55 (04) :585-612